Clinical trial
A Study of GENEVAX-HIV, a Possible Vaccine
NCT00002232 · Wyeth-Lederle Vaccines, Industry · Completed
Key facts
| NCT number | NCT00002232 |
|---|---|
| Title | A Study of GENEVAX-HIV, a Possible Vaccine |
| Official title | GENEVAX-HIV (APL 400-003), a Candidate DNA Vaccine: A Pilot Study of GENEVAX-HIV Given by Intramuscular or Intradermal Administration in HIV Seronegative Volunteers |
| Lead sponsor | Wyeth-Lederle Vaccines, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | HIV Infections, HIV Seronegativity |
| Intervention type | Biological |
| Interventions | APL 400-003 |
| First posted | Aug 31, 2001 |
| Last update posted | Jun 24, 2005 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: